Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigation of Radiation Retinopathy (RadiRet Study)
2011-004463-69Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of ranibizumab in Radiation chorioretinopathy (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Change from baseline in BCVA over 6 months. Started Aug 2012; status: terminated.
02
Drugs
ranibizumab
03
Conditions
Radiation chorioretinopathy
Beyond the preview
Go deeper on 2011-004463-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004463-69.